|
|
Parkinson's Disease News covers
all significant new research, reports, books, and resources concerning
Parkinson's Disease.
Articles are chosen on the basis
of their medical significance or potential interest. Our overwhelming priority
is the facts, regardless of whether they contradict prevailing views or vested
interests. Analysis and further information are provided
either to explain the background or implications, or to
balance misleading claims. If you notice errors or inadequacies, or dispute what is
written, or want to propose articles, please
e-mail
[email protected].
7th April 2017 - New research
P2B 001 (RASAGILINE AND PRAMIPEXOLE) FOR PARKINSON'S DISEASE
|
CLICK HERE
FOR A
PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE |
P2B 001 is a novel combination of (1) slow release and (2) low dose
rasagiline and pramipexole for synergistic use in early Parkinson's Disease
that is presently in development. For more information go to
P2B 001
Rasagiline is a MAO
inhibitor for use in treating Parkinson's Disease. For more information go
to
Rasagiline Pramipexole is a dopamine agonist that is also for use in
Parkinson's Disease. For more information go to :
Pramipexole
 People
with early Parkinson's Disease were assessed when taking either : P2B 001
(0.3mg pramipexole / 0.75mg rasagiline), P2B001 (0.6mg pramipexole / 0.75mg
rasagiline) or a placebo. The most effective of these was P2B 001 with a
higher dose of pramipexole, followed by P2B 001 with a lower dose of
pramipexole. Significant benefits were observed for both doses in :
Parkinson Disease Quality of Life Scale-39 scores, the UPDRS (Parkinson's
Disease) motor score, and activities of daily living. The adverse effects of
P2B 001 were comparable to the use of a placebo apart from transient nausea
and somnolence, which were more common with P2B 001 treatment. The
researchers suggest that P2B 001 offers a promising treatment option for use
in early Parkinson's Disease with good clinical efficacy and a low risk of
adverse effects, in a way that can not be achieved by taking each drug on
their own.
Reference : Movement Disorders [2017] Apr 3 [Epub
ahead of print] (C.W.Olanow, K. Kieburtz, M.Leinonen, L.Elmer, N.Giladi,
R.A.Hauser, O.S.Klepiskaya, D.L.Kreitzman, M. F.Lew, D.S.Russell, S.Kadosh,
P.Litman, H.Friedman, N.Linvah)
Complete abstract For more news go to
Parkinson's Disease News
 E-MAIL NOTIFICATION : If you would like to be
notified by e-mail when any new articles
are added to Parkinson's Disease News, please merely
e-mail
[email protected] with the message
"subscribe". No form of identity is required. E-mail addresses are
not used for any other purpose.
|
|
|
|
 |
THE
COMPREHENSIVE GUIDE TO PARKINSON'S DISEASE
The Comprehensive Guide to Parkinson's
Disease, which is fully referenced, and over 800 pages long, is
the most comprehensive book concerning Parkinson's Disease. It includes the history of Parkinson 's Disease, famous
people with Parkinson's Disease, the complete biochemisty of
Parkinson's Disease,
its cytology and cytological effects,
anatomy and anatomical effects, physiology and physiological
effects, symptoms of every system in the body, the diagnosis methods
(observational, technological, chemical), biochemical causes, all the toxic causes, all the genetic causes, all the
pharmacological causes, all the medical disorders that cause Parkinson's Disease
symptoms, its treatments (biochemical, pharmacological,
surgical, natural, exercise methods, technological methods),
including all those treatments that exist and all those treatments
presently being developed, Parkinson's Disease organisations,
Parkinson's Disease web sites, and books on Parkinson's Disease
nursing.
CLICK HERE FOR MORE DETAILS |
|
|
|
.gif)
.gif)